ZHEJIANG POLY PHARM
GenericsZHEJIANG POLY PHARM is a generic drug manufacturer focused on Infectious Disease, Respiratory, Dermatology.
ZHEJIANG POLY PHARM's Key Drugs
ZHEJIANG POLY PHARM's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
ZHEJIANG POLY PHARM's Recent FDA Approvals
New NDA/BLA approvals for ZHEJIANG POLY PHARM over the last two years — novel drugs only, excluding generics and label supplements.
ZHEJIANG POLY PHARM's Therapeutic Areas
ZHEJIANG POLY PHARM's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Respiratory. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ZHEJIANG POLY PHARM's Top Competitors
ZHEJIANG POLY PHARM's closest competitors by therapeutic-area and drug-target overlap include Pfizer, APOTHECON, and Bristol-Myers Squibb. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ZHEJIANG POLY PHARM Pipeline Snapshot
Active clinical trials for ZHEJIANG POLY PHARM across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2023-07-27
- Latest
- 2026-02-23
- Applications
- 7